01Project Background
Against the backdrop of high-quality development in the pharmaceutical industry, digital management has become a key driver for enterprises to enhance their quality compliance standards and operational efficiency. As a leading domestic pharmaceutical enterprise, Hunan Fangsheng Pharmaceutical has always adhered to quality as its core and is committed to optimizing its management system through digital technologies. The launch of this DMS (Document Management System) digital project marks another major upgrade for Fangsheng Pharmaceutical in the field of quality management. It aims to achieve the standardization, efficiency, and traceability of document management through digital means, injecting new impetus into the enterprise’s high-quality development.
02Project Kickoff Meeting
To fully advance the implementation of the DMS digital project, Fangsheng Pharmaceutical and Xingdi jointly held the "Fangsheng Pharmaceutical DMS Digital Project Kickoff Ceremony." Directors and project team members from relevant departments of Fangsheng Pharmaceutical—including the Quality Department, Production Department, R&D Department, and Information Technology Department—gathered together with the Xingdi project team to jointly discuss the development path and future value of digital document management.
At the kickoff ceremony, the two parties conducted in-depth exchanges on topics such as the digital upgrading of document management, compliance assurance, and efficiency improvement. They also reached a consensus on the project implementation plan, laying a solid foundation for the smooth advancement of the project.
03Leader's Speech
Dr. Xiao Liang, Chairman of Hippocrates
At the Project Kickoff Ceremony, Dr. Xiao Liang reviewed the entire process—from Hippocrates’s participation in Fangsheng Pharmaceutical’s rigorous supplier selection to the final conclusion of their cooperation. He stated that Hippocrates’s Aotai® Digital Platform will help Fangsheng Pharmaceutical achieve a comprehensive digital transformation of document management, meet domestic and international industry regulatory requirements, and at the same time enhance employees' compliance awareness and operational standardization. Dr. Xiao emphasized that Hippocrates will fully leverage its technological advantages to ensure the high-quality delivery of the project and provide solid support for Fangsheng Pharmaceutical’s digital transformation.
Li Ziqiang, General Manager of the Quality Department of Fangsheng Pharmaceutical
Mr. Li Ziqiang pointed out that during the selection process, Hunan Fangsheng Pharmaceutical conducted multiple rounds of inspection and comparison, and was ultimately impressed by the full-process integrated design concept and outstanding product performance of Hippocrates’s Aotai® Platform. He put forward clear requirements for the project team, hoping that all members would advance in strict accordance with the project plan. Under the guidance of Xingdi’s professional team, they should ensure that each milestone is achieved on schedule, eventually realizing the complete success of the project and opening up a new prospect for the upgrading of Fangsheng Pharmaceutical’s quality management system.
04 About OwlTrust® Digital Platform
Developed dedicatedly by Hippocrates, OwlTrust® (OwlTrust) is an integrated digital platform for quality and compliance. It brings together experts in the GMP industry and digital field, and is built in strict accordance with standards and regulations including GMP, cGMP, ICH, FDA 21 CFR Part 11, EU-GMP (Annex 11), and ISPE GAMP 5. With "Quality & Compliance Expert" as its management philosophy and market positioning,OwlTrust® empowers pharmaceutical enterprises to enhance the level of quality and compliance, meet industry regulatory requirements, accelerate the launch of more safe, effective, and quality-reliable products, and realize greater health value.
05 Introduction of Both Parties
About Fangsheng Pharmaceutical
Hunan Fangsheng Pharmaceutical (Stock Code: 603998.SH) is a modern pharmaceutical enterprise focusing on the R&D, production and sales of traditional Chinese medicine (TCM). Since its establishment in 2002, it has always taken inheriting and innovating TCM culture as its mission and is committed to providing high-quality pharmaceutical products for public health. Headquartered in Changsha, Hunan, the company has developed into a backbone force in China's TCM industry with its outstanding R&D capabilities and market influence.
Fangsheng Pharmaceutical has achieved remarkable results in the field of TCM innovation. In 2024, the company was listed in the "Top 20 TCM Innovation Enterprises" and ranked 7th, demonstrating its strong strength in TCM R&D. During 2023-2024, Fangsheng Pharmaceutical ranked 12th in the "TCM Ranking", further confirming its leading position in the industry. In 2025, its owned brand "Xuesaitong" (a TCM brand for cardiovascular and cerebrovascular diseases) won the first place in the relevant ranking. This achievement not only reflects Fangsheng Pharmaceutical's excellent quality in TCM products for cardiovascular and cerebrovascular diseases, but also highlights its outstanding accomplishments in brand building and marketing promotion.
The company has a rich and diverse product portfolio, covering multiple fields such as cardiovascular and cerebrovascular diseases, respiratory diseases, and anti-infection. Among them, core products like Xuanqi Jiangu Tablets, Qiangli Pipa Ointment, and Tenghuang Jiangu Tablets are highly praised in the market, winning the trust of a large number of consumers with their excellent efficacy and good reputation. Fangsheng Pharmaceutical attaches great importance to R&D and innovation; its R&D expenditure exceeded 100 million yuan for the first time in 2023. This investment not only provides a solid guarantee for the continuous upgrading of products, but also helps the company gain an advantage in the fierce market competition.
The company has long remained among the "Top 50 Chinese Patent TCM Enterprises", a ranking that fully demonstrates its profound heritage and strong competitiveness in the patent TCM field. With its excellent product quality, extensive market coverage, and positive brand image, Fangsheng Pharmaceutical has won high recognition both within and outside the industry.
About Hippocrates
The name "Hippocrates" is a transliteration of "Hippocrates"—the "Father of Ancient Greek Medicine". As a leading digital solution provider in China's life and health industry, Hippocrates is committed to helping life and health enterprises (including pharmaceutical, medical device, and cosmetics companies) achieve digital transformation through innovative technologies and products.
Its business covers fields such as GMP quality management, digital factory construction, GVP pharmacovigilance, and GCP clinical research. The company has served over 200 customers in China, established overseas branches, and built cooperative relationships with a number of multinational enterprises.
Hippocrates’s owned brands include Hippocrates Health and Ruilesen Consulting.
